Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer-Reference-Cited by-同舟云学术

Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer

Published:2008-10 Issue:4 Volume:54 Page:805-815
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Van Poppel Hendrik,Tombal Bertrand,de la Rosette Jean J.,Persson Bo-Eric,Jensen Jens-Kristian,Kold Olesen Tine

Publisher

Elsevier BV

Subject

Urology

Reference21 articles.

1. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007

2. Guidelines on prostate cancer;Heidenreich,2007

3. A peptide inhibitor of luteinizing hormone-releasing hormone (LH-RH);Coy;J Clin Endocrinol Metab,1973

4. GnRH-receptor interaction. V. Down-regulation of pituitary receptors for GnRH in ovariectomised ewes by infusion of homologous hormone;Nett;Biol Reprod,1981

5. Pituitary desensitisation and the regulation of pituitary gonadotropin-releasing hormone (GnRH) receptors following chronic administration of a superactive GnRH analog and testosterone;Heber;Life Sci,1982

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection of prostate cancer therapy strategy under early androgen suppression treatment;Communications in Nonlinear Science and Numerical Simulation;2024-05

2. Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study;Investigative and Clinical Urology;2023

3. An observational multicenter study to evaluate the efficacy and safety of degarelix® for prostate cancer in routine clinical practice;Cancer Urology;2022-08-14

4. Relugolix in the management of prostate cancer;Expert Review of Anticancer Therapy;2022-07-27

5. Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery;Advanced Drug Delivery Reviews;2022-07